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Abstract
Background: The development of DNA amplification for the direct detection of M. tuberculosis
from clinical samples has been a major goal of clinical microbiology during the last ten years.
However, the limited sensitivity of most DNA amplification techniques restricts their use to smear
positive samples. On the other hand, the development of automated liquid culture has increased
the speed and sensitivity of cultivation of mycobacteria. We have opted to combine automated
culture with rapid genotypic identification (ARDRA: amplified rDNA restriction analysis) for the
detection resp. identification of all mycobacterial species at once, instead of attempting direct PCR
based detection from clinical samples of M. tuberculosis only.
Results: During 1998–2000 a total of approx. 3500 clinical samples was screened for the presence
of M. tuberculosis. Of the 151 culture positive samples, 61 were M. tuberculosis culture positive. Of
the 30 smear positive samples, 26 were M. tuberculosis positive. All but three of these 151
mycobacterial isolates could be identified with ARDRA within on average 36 hours. The three
isolates that could not be identified belonged to rare species not yet included in our ARDRA
fingerprint library or were isolates with an aberrant pattern.
Conclusions: In our hands, automated culture in combination with ARDRA provides with
accurate, practically applicable, wide range identification of mycobacterial species. The existing
identification library covers most species, and can be easily updated when new species are studied
or described. The drawback is that ARDRA is culture-dependent, since automated culture of M.
tuberculosis takes on average 16.7 days (range 6 to 29 days). However, culture is needed after all to
assess the antibiotic susceptibility of the strains.
Background
Rapid and accurate detection, identification and suscepti-
bility testing of mycobacteria remains important i) be-
cause the overall incidence of tuberculosis is increasing,
also due to the HIV pandemic [1], ii) because of the in-
creasing resistance to antituberculous agents [2] and iii)
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because an increasing number of mycobacterial species
are being recognized as potentially pathogenic [3]. The
importance of M. avium infection has increased in HIV pa-
tients [4], and clinical infections have been described with
species like M. heidelbergense[5],  M. conspicuum[6],  M.
branderi [7] and M. interjectum[8,9], which have been rec-
ognized only recently.
Current DNA amplification based diagnostic tests are ex-
pensive, have limited senstivity, are usually restricted to
the detection of M. tuberculosis only and provide no or
limited information on susceptibility (e.g. rifampicin on-
ly: RifTB LiPA, Innogenetics, Zwijnaarde, Belgium). There-
fore, the need for culture has not been circumvented. The
CDC decided to restrict the use of genotypic tests to con-
firmation of smear positive samples, so that they cannot
be used to test the large number of specimens processed
for mycobacterial detection every year in an average labo-
ratory [10]. Only recently, the enhanced AMTD (Gen-
Probe, San Diego, CA) gained FDA approval for direct de-
tection of M. tuberculosis from smear-negative samples,
but several problems are reported [e.g. [11], and the high
costs keep restricting its use.
Here, we present our findings with the use of ARDRA [12]
for the identification of Mycobacterium species. The meth-
od consists of amplification of the 16S rRNA gene (rDNA)
and subsequent restriction digestion of the amplicon. The
restriction patterns obtained with different restriction en-
zymes and combination of these patterns into a restriction
profile was shown to enable identification of most clini-
cally important mycobacteria by comparison of the ob-
tained profiles with a library of ARDRA profiles obtained
for reference strains of different species [12]. This PCR-
RFLP analysis of the 16S rRNA gene, was published almost
simultaneously with the more widely used technique
(known as PRA), which is based on the amplification of
the hsp65 gene [13–15].
Results
The initial study describing the applicability of ARDRA for
the identification of mycobacteria [12] used universal bac-
terial primers. However, this sometimes resulted in the
false positive amplification from decontaminated sam-
ples of organisms other than mycobacteria. Therefore
primers were developed, aimed at more specific amplifica-
tion of mycobacteria. During the three year evaluation pe-
riod, of which the results are reported here, amplification
of nonmycobacterial organisms occurred in two cases.
These organisms, namely Corynebacterium glutamicum and
Actinomyces odontolyticum, stained acid fast on direct smear
and are relatives of the mycobacteria.
The restriction patterns obtained with the enzymes HhaI
(isoschizomer of CfoI), MboI and RsaI for the different spe-
cies are numbered arbitrarily and are presented in Figures
1, 2 and 3 respectively. Figures 4,5,6 represent the restric-
tion patterns obtained when digital restriction is carried
out with the same enzymes on published GenBank se-
quences. The combination of these patterns is designed as
ARDRA profiles and these are listed in Table 1. For exam-
ple, strains of the M. tuberculosis complex can be recog-
nized by an ARDRA profile 1-1-1, while M. grodonae
strains have ARDRA profile 8-4-2. For some species the
ARDRA pattern obtained with enzyme is already charac-
teristic, e.g. HhaI 1 is observed only for species of the M.
tuberculosis complex.
Most mycobacterial species could be readily identified by
comparison of the obtained ARDRA profile with the pro-
files from Table 1. The species of the M. tuberculosis com-
plex can not be differentiated on the basis of the 16S
rDNA sequence, and therefore restriction digestion of this
gene could not either. Most of the clinically relevant and
the most abundant species were readily differentiated
from each other. The following species could not be dif-
ferentiated from each other after digestion with HhaI,
MboI, RsaI and BstUI: M. gastri and M. kansasii (1'-4-1-1),
M. bohemicum, M. haemophilum and M. malmoense (1'-4-1-
3), MCRO6 and M. nonchromogenicum (2-6-4-7), M. chelo-
nae group I, M. abscessus and M. immunogenicum (3-3-6-
2'), M. farcinogenes, M. fortuitum, M. senegalense and M.
septicum (4-1-6-7), M. simiae and M. lentiflavum (5-7-6-2'),
M. goodii and M. smegmatis (10-1-2-2'), M. tusciae and M.
flavescens (10-1-6-2'), and finally M. genavense and M. tri-
plex (10-7-6-2').
During 1998–2000, approximately 3500 samples were
sent to the laboratory for direct smear examination and
mycobacterial culture. Of these, 151 specimens, from 149
patients, were culture positive, and 20% of these were also
smear positive. Table 2 summarizes the obtained identifi-
Figure 1
HhaI (CfoI) restriction patterns of amplified mycobacterial
16S rRNA genes. Legend: M: marker (100 base pair ladder,
Fermentas, Vilnius, Lithuania)BMC Microbiology 2002, 2 http://www.biomedcentral.com/1471-2180/2/4
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cations. For 148 of the 151 isolates, identification by AR-
DRA was straightforward and was obtained after an
average of 36 hours after receipt of the cultured strain.
Only three difficulties were encountered. One isolate pre-
sented with the ARDRA profile 5-4-6, not present in the
ARDRA library at that time. Sequencing lead to an identi-
fication as M. interjectum[8], a species that was not yet cov-
ered by the library. A second isolate was first misidentified
as M. xenopi (profile 1'-4-3), but later on it was observed
that the HhaI fingerprint differed clearly from the M.
xenopi HhaI 1' pattern by its low molecular size fragments
(Figure 1). This HhaI pattern was designated HhaI 1", re-
sulting in the unique ARDRA profile 1"-4-3. The isolate
was identified as M. heckeshornense by sequencing of the
16S rRNA gene, and can now also be identified by AR-
DRA. The third problematic isolate had ARDRA profile 1-
1-3, again a profile that had never been observed for any
mycobacterial strain studied thus far. Sequencing of the
16S rRNA gave a 99.8 % similarity to the 16S rRNA se-
quence of the type strain of M. tuberculosis. The sequence
revealed a mutation at E. coli position 646 from A to G,
abolishing the RsaI restriction site GTAC at that place. This
mutation shifts the RsaI pattern 1 to RsaI pattern 3 because
the two fragments of resp. 620 and 180 bp are replaced by
a single fragment of 800 bp. Further morphological and
biochemical tests revealed an identification as probably
M. africanum, one of the species of the M. tuberculosis com-
plex. It should be mentioned that M. africanum reference
strains used in a previous study [12], were found to have
the regular M. tuberculosis complex ARDRA profile 1-1-1.
To construct artificial ARDRA patterns for the recently de-
scribed species, we applied the programme RFLP on the
published Genbank sequences. The resulting, theoretical-
ly to be expected, ARDRA profiles are presented in Table 1.
M. tuberculosis was found to be the most prevalent species,
with 40% of the isolates, followed by M. gordonae and M.
xenopi, species mostly isolated form non-pulmonar sam-
ples with low clinical relevance.
Similarity calculation of published sequences and of se-
quences obtained in this study (Figure 8) indicates that
the M. abscessus/M. chelonae complex (M. chehnae, M. ab-
scessus and M. immunogenum) clusters separately from all
other mycobacteria. Portaels et al.[16] described the pres-
ence of four groups within the M. abscessus/M. chelonae
complex, based on the 16S–23S spacer sequences, as used
in the INNO-LiPA Mycobacteria kit (Innogenetics, Zwi-
jnaarde, Belgium). Groups II and IV consisted of genuine
M. chelonae strains, which were usually from environmen-
tal sources. These two groups have characteristic ARDRA
profiles, namely 13-3-6 and 3-3-5. Group III, which was
found to represent genuine M. abscessus and M. chelonae
group I, which most probably corresponds with M. immu-
nogenum, a M. abscessus-like species that was recently de-
scribed as being frequently involved in bronchoscope
related pseudo-outbreaks [17], can not be distinguished
from each other by ARDRA (profile 3-3-6). Strains of
groups I and III are usually isolated from clinical samples,
with only group III strains (genuine M. abscessus) being
pathogenic [16].
Figure 2
MboI restriction patterns of amplified mycobacterial 16S
rRNA genes. Legend: M: marker (100 base pair ladder, Fer-
mentas, Vilnius, Lithuania)
Figure 3
RsaI restriction patterns of amplified mycobacterial 16S
rRNA genes. Legend: M: marker (100 base pair ladder, Fer-
mentas, Vilnius, Lithuania)BMC Microbiology 2002, 2 http://www.biomedcentral.com/1471-2180/2/4
Page 4 of 12
(page number not for citation purposes)
M. tuberculosis was the most frequently cultured species
(40% of all culture positives), followed by M. gordonae
(27%) and M. xenopi (15%) The latter two species were
mostly isolated from non-pulmonar samples. 46% of the
samples culture positive for M. tuberculosis, were auramine
staining positive, and the average time of incubation until
a positive liquid culture of M. tuberculosis was 12.9 days
for the auramine positive samples and 20 days for au-
ramine negative samples. The range of time to positivity
for all M. tuberculosis positive samples was between 6 and
29 days. The average culture times for species other than
M. tuberculosis, as far as data were available, are presented
in Table 2.
Discussion
Restriction analysis of the amplified 16S rRNA gene, or
amplified rDNA restriction analysis (ARDRA) was intro-
duced into the Laboratory for Bacteriology of the Ghent
University Hospital for the identification of cultured my-
cobacteria in 1993 [12]. Since then, several comparable
approaches, based on restriction digestion of the ampli-
fied rRNA genes and spacer regions have been described
[18–21]. During that period, this approach has been up-
dated and refined. This was possible due to some techni-
cal changes, like increased quality control of gel
electrophoresis and pattern interpretation and the use of
primers specific for species of the order of the Actinomyc-
etales instead of universal bacterial primers. Refinement
was also possible because of the improvement of myco-
bacterial taxonomy and the possibility offered by PCR-
RFLP techniques, like ARDRA, to easily adapt to this new
information. Indeed, when new species are described,
there is no need to develop new probes or primers. In-
stead, new ARDRA profiles can be easily added to the ex-
isting library. Also, ARDRA profiles for newly described
species can be predicted by applying computer aided di-
gestion of the available GenBank sequences, given the
availability of sequences of sufficient quality [22].
ARDRA was found to be a useful tool for identification of
mycobacterial isolates in a clinical routine laboratory, be-
cause of its speed – compared to phenotypic identifica-
tion, its reliability, practical applicability, flexibility and
the possibility to identify most nontuberculous mycobac-
teria together with and at the same cost as M. tuberculosis,
Figure 4
HhaI (CfoI) restriction patterns of mycobacterial 16S rRNA
genes, theoretically calculated using RFLP (Applied Maths)
and published GenBank sequences. Graphical representation
and table of restriction fragment lengths for each of the pos-
sible patterns.
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Pattern CfoI restriction fragment lengths (bp)
1 408, 385, 312, 181, 168
1' 408, 388, 312, 187, 160
1" 408, 388, 312, 196, 157
2 408, 387, 347, 312
3 408, 385, 346, 300
4 408, 387, 225, 190, 155, 75
5 408, 387, 225, 187, 160, 75
7 408, 362, 225, 192, 152, 75
8 654, 408, 386
10 408, 389, 347, 225, 75
13 385, 346, 302, 300, 106
14 408, 360, 346, 312, 25
15 422, 408, 363, 225, 25
16 406, 364, 344, 225, 74, 25
Figure 5
MboI restriction patterns of mycobacterial 16S rRNA genes,
theoretically calculated using RFLP (Applied Maths) and pub-
lished GenBank sequences. Graphical representation and
table of restriction fragment lengths for each of the possible
patterns.
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1 710, 456, 121, 94, 51, 17
2 808, 508, 121, 17
3 702, 507, 120, 93, 17
4 808, 457, 121, 51, 17
6 718, 411, 121, 96, 94
7 1253, 120, 51, 17BMC Microbiology 2002, 2 http://www.biomedcentral.com/1471-2180/2/4
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Table 1: Library of ARDRA profiles (combination of restriction patterns) obtained for mycobacterial species.
Species Genbank Number HhaI MboI RsaI BstUI Reference strains useda
M. tuberculosis c o m p l e x X 5 2 9 1 7 1111I T G  8021, IPB 92/0805
M. conspicuum X88922 1' 1 2 2
M. intracellulare X 5 2 9 2 7 1 '223I T G   5913, ITG 5917
M. gastri X52919 1' 4 1 1
M. kansasii M29575 1' 411I T G   8201
M. bohemicum AJ277283 1' 4 1 3
M. haemophilum U 0 6 6 3 8 1 '413I T G   3065
M. malmoense AF152560 1' 413I T G   940611
M. szulgai X 5 2 9 2 6 1 '421I T G   4981
M. scrofulaceum X 5 2 9 2 4 1 '423I T G   4988
M. xenopi X 5 2 9 2 9 1 '432I T G   4986
M. heckeshornense AF174290 1' 4 3 4
M. marinum AF251565 2111I T G   1728
M. asiaticum M29556 2125I T G   8182
M. terrae X 5 2 9 2 5 2142I T G   4922
M. ulcerans Z13990 2191I T G   724, ITG 1837
M. avium AF306455 2223I T G   4991, ITG 2666
M. botniense AJ012756 2432
M. terrae-like MCRO6b X 9 3 0 3 2 2647
M. nonchromogenicum X 5 2 9 2 8 2647I T G   4980
M. phlei M29566 3162 '
M. elephantis AJ010747 3183 '
M. chelonae group IVc AJ416940 3352 ' I T G   7701
M. abscessus group IIIc AJ419970 3362 ' I T G  9 8 - 1 2 9 6
M. chelonae group 1c AJ419969 3362 ' I T G  9 5 - 0 0 2 6
M. immunogenum AJ011771 3362 ' I T G  9 8 - 1 2 8 9
M. farcinogenes AF055333 4167
M. fortuitum X 5 2 9 3 3 4167S L Z  A 0 4 6
M. senegalense M29567 4167
M. septicum AF111809 4167I T G   4166
M. intermedium X 6 7 8 4 7 5461 '
M. interjectum AJ272088 5462 ' I T G  9 6 - 1 1 6
M. heidelbergense X 7 0 9 6 0 5482 '
M. simiae X 5 2 9 3 1 5762 ' I T G   4485
M. lentiflavum X 8 0 7 6 9 5762 '
M. peregrinumd X 5 2 9 2 1 7169I T G  9 9 - 2 0 6 9 ,  A T C C  1 4467
M. gordonae M29563 8425I T G   7838
M. wolinskyi Y12871 10 1 1 2'
M. speciesa AF028712 10 1 1 2'
M. goodii Y12872 10 1 2 2'
M. smegmatis AJ131761 10 1 2 2' ITG 4995
M. kubicae AF133902 10 1 6 1'
M. tusciae AF058299 10 1 6 2'
M. flavescens X52932 10 1 6 2' VUB A016
M. genavense X60070 10 7 6 2' ITG 97-102
M. triplex U57632 10 7 6 2'
M. chelonae group IIc AJ419968 13 366I T G  9 6 - 0 2 9 5
M. branderi X82234 14 1 1 9
M. celatume L08169 14 1 1 10
M. triviale X88924 15 1 10 10'
M. aurum X55595 16 1 6 8
a. ITG: Institute for Tropical Medicine, Antwerp, Belgium; IPB: Institute Pasteur du Brabant, Brussels, Belgium; SLZ: Streeklaboratorium Zeeland, 
Goes, the Netherlands; VUB: Free University of Brussels, Brussels, Belgium. b. Strains designated MCRO6 have been studied by Turenne et al.[22] 
and Torkko et al.[33]. c. Sequences determined in this study. Roman numbering according to Portaels et al.[16], who distinguished four groups 
within the M. abscessus/M. chelonae complex, based on the 16S–23S rRNA spacer region. d. The GenBank sequence (AF058712) of strain ATCC 
14467, submitted to GenBank as M. peregrinum, did not cluster within the M. fortuitum complex (Figure 8) and was highly similar to sequence 
Y12871 (M. wolinskyi). Moreover, the ARDRA profile calculated from sequence AF058712 (10-1-1-2') did not correspond with the profile we 
obtained for strain ATCC 14467 (4-1-6-7). The sequence obtained in this study from strain ATCC 14467 (submitted as AJ422046) was identical to 
the M. fortuitum sequence X52933. Sequence AF058712 is indicated as M. species in the table. e. Received as M. xenopi.BMC Microbiology 2002, 2 http://www.biomedcentral.com/1471-2180/2/4
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at an affordable price. Of the 151 isolates during the last
three years, 148 could be identified without problems.
The other three isolates, respectively M. interjectum, M.
heckeshornense and an M. africanum-like strain, should be
identifiable when met again in the future, since they pre-
sented with specific ARDRA profiles.
Practical applicability of ARDRA
The theoretical turnaround time of ARDRA is 6 hours, and
the average identification time in practice during this
study was 36 hours. It should be emphasized that the
technique was not fully implemented in the routine labo-
ratory, but was carried out by the research laboratory tech-
nicians, which means that the practical turnaround time
should be far less than 36 hours in a routine diagnostic
laboratory. Technically, ARDRA is nondemanding, com-
prising only basic molecular biology techniques like sim-
ple DNA extraction, PCR, restriction digestion and
submarine agarose gel electrophoresis.
General considerations
We have addressed previously the several limitations of
molecular biology based detection in diagnostic bacteriol-
ogy [23]. Others agree that the expectations that DNA am-
plification technologies would supplant microscopy,
accurately predict culture results and provide an immedi-
ate definitive diagnosis were premature and that these
claims have to be replaced with a more realistic view of the
limitations and of the practical value of molecular diag-
nostics of tuberculosis [10,24,25]. Also the expectation
that susceptibility would be carried out solely by means of
DNA technology, had to be moderated [26]. Despite the
fact that during the last ten years a tremendous effort,
both in academic and commercial research, has been put
into the applicability of nucleotide amplification tech-
niques for the detection of mycobacteria directly from
clinical samples, the CDC approved application of these
techniques only for smear positive samples. This impli-
cates that for 52% of the culture positive samples with M.
tuberculosis encountered in this study, DNA technology
would not have accelerated detection, since microscopy
Figure 6
RsaI restriction patterns of mycobacterial 16S rRNA genes,
theoretically calculated using RFLP (Applied Maths) and pub-
lished GenBank sequences. Graphical representation and
table of restriction fragment lengths for each of the possible
patterns.
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Pattern RsaI restriction fragment lengths (bp)
1 616, 355, 167, 148, 99, 53, 16
2 556, 355, 167, 148, 99, 60, 53 ,16
3 788, 355, 148, 101, 53, 16
4 391, 355, 167, 167, 148, 99, 59, 55, 16
5 373, 237, 171, 167, 147, 117, 98, 59, 53, 16
6 373, 355, 171, 167, 148, 98, 60, 53, 16
8 433, 355, 171, 167, 148, 99, 53, 16
9 616, 502, 167, 102, 53, 16
10 604, 205, 167, 150, 148, 100, 53, 16
Figure 7
BstUI restriction patterns of mycobacterial 16S rRNA genes,
theoretically calculated using RFLP (Applied Maths) and pub-
lished GenBank sequences. Graphical representation and
table of restriction fragment lengths for each of the possible
patterns.
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Pattern BstUI restriction fragment lengths (bp)
1 378, 258, 227, 205, 166, 117, 68, 36
1’ 378, 258, 227, 204, 166, 105, 68, 36
2 521, 378, 203, 166, 117, 68
2’ 521, 378, 200, 166, 105, 68
3 485, 378, 202, 166, 117, 68, 35
3’ 485, 378, 205, 166, 117, 68, 36
4 487, 378, 166, 155, 117, 68, 54, 36
5 378, 294, 228, 196, 166, 117, 68
6 521, 448, 203, 166, 119
7 522, 378, 166, 153, 105, 68, 48
8 378, 362, 166, 160, 150, 105, 68, 50
9 378, 229, 205, 166, 160, 134, 117, 68
10 378, 360, 202, 166, 160, 117, 68
10’ 378, 363, 203, 166, 160, 105, 68BMC Microbiology 2002, 2 http://www.biomedcentral.com/1471-2180/2/4
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was negative. Recently, AMTD2 (GenProbe) gained FDA
approval for testing smear negative sputa, but the cost of
the technique keeps limiting its use to only those smear
negative samples with strong clinical suspicion of tuber-
culosis. Moreover, since this kind of direct detection am-
plification technology is technically demanding or
requires specialized equipment and kits, many laborato-
ries carry out these tests only at well-set time intervals [e.g.
[11]], delaying diagnosis with several days on average,
and as such loosing some of the time gain offered by these
direct detection methods. As a final remark, one should
keep in mind that direct detection without direct antimi-
crobial susceptibility testing does not obviate the need for
culture after all.
ARDRA compared to other culture based genotypic identi-
fication techniques
ARDRA and other gene restriction techniques
[14,15,21,27,28] have been developed as a practical short
cut to full sequence determination. From this study and
others it is clear that the discriminatory power of these
RFLP approaches for identification of mycobacteria is al-
most as high as that of sequencing. The discriminatory
power and reliability of a commercially available rRNA-
spacer based hybridisation assay (INNO-LiPA Mycobacte-
ria) is high, but again this approach is somewhat more la-
borious and more expensive than in house PCR-RFLP-
based techniques. Restriction digestion of a 439 bp stretch
of the hsp65 gene for identification of mycobacteria was
described almost simultaneously with ARDRA and desig-
nated PCR-RFLP Analysis (PRA) [15]. Several laboratories
have published their experience using this technique [e.g.
[14,27,28]]. Possible drawbacks of hsp65 gene restriction
analysis are the smaller sized restriction fragments and the
higher intraspecific variability, which may make interpre-
tation more difficult. The small size differences have led to
the use of polyacrylamide gel electrophoresis [27], which
is less practical than agarose gel electrophoresis and the
interpretation difficulties in general have led to reconsid-
eration of the hsp65 gene restriction profiles used thus far
[28]. Comparable remarks can be made for PCR-RFLP
analysis of the rRNA spacer region [21].
Future developments
At present, in an effort to have the best of both worlds, we
are performing a double PCR, directly on smear positive,
decontaminated samples, extracting DNA with the com-
merially available QiaAmp Tissue kit (Qiagen, Hilden,
Germany). One PCR attempts to amplify the full length
16S rRNA gene (1500 bp), which can be used for ARDRA,
at an annealing at 55°C, and one PCR amplifies a 123 bp
region of the IS6110 at an optimal annealing of 68.6°C
[29]. Both PCRs are carried out simultaneously in a T-gra-
dient thermocycler (Biometra, Göttingen, Germany), pro-
grammed to have both annealing temperatures in the 96
well block. In case of the presence of the 123 bp fragment
on an agarose gel, the identification of M. tuberculosis is
completed, and can optionally be confirmed with AR-
DRA. Due to the higher sensitivity of the IS6110 PCR
compared to the rDNA PCR, we could amplify the IS6110
fragment of M. tuberculosis directly from all smear positive,
M. tuberculosis culture positive samples thus far. In case
only the 16S rDNA fragment of 1500 bp is present, the ab-
sence of M. tuberculosis can be confirmed by ARDRA which
Table 2: Distribution of the Mycobacterium species during 1998–2000 in the Ghent University Hospital, number of smear positives and 
time to positivity of culture.
Mycobacterium species Number of isolates (%) Number of samples positive on
direct smear a (% of culture positive)
Average time until positive culture in days
(smear positives; negatives)
M. tuberculosis complex 61 (40) 26 (46b) 16.7 (12.9; 20)
M. avium 12 2 6.5
M. heckeshornense 1 1 32.5
M. chelonae 40 1 8
M. fortuitum 2 0 35.5
M. gordonae 41 (27) 1 22.3
M. interjectum 1 0 30.5
M. intracellulare 1 0 11.6
M. kansasii/M. gastri 20 N o  d a t a
M. malmoense 10 N o  d a t a
M. szulgai 3 0 20.3
M. xenopi 22 (15) 0 38.1
Total 151 40 (26)
a: No data for 6 of the 61 samples. All six of these samples were M. tuberculosis culture positive. b. Calculated as 26 positives on a total of those 56 
culture positives for which data on smear positivity were available.BMC Microbiology 2002, 2 http://www.biomedcentral.com/1471-2180/2/4
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also immediately provides with the identification of the
Mycobacterium species other than tuberculosis. Thus far,
this yielded in all cases an identification as a nontubercu-
lous strain, confirming the absence of M. tuberculosis. Also
in case both amplifications of the smear positive sample
remain negative, this can be interpreted as the absence of
M. tuberculosis. A positive culture is then awaited to iden-
tify the nontuberculous organism with ARDRA.
Taxonomical considerations
This study also confirmed the robustness of ARDRA based
identifications. For example, for the first study [12], we re-
ceived strains identified by reference laboratories as M.
avium and M. xenopi, using phenotypic methods. During
the first study already, some strains that had been sent as
M. avium could be shown by ARDRA (and subsequent
confirmation by another laboratory) to be M. scrofu-
laceum. For M. xenopi, ARDRA indicated the presence of
several groups. In the meantime mycobacterial taxonomy
has been refined and the groups we indicated as M. xenopi
A and M. xenopi B [12] appear to correspond to genuine
M. xenopi, resp. M. celatum (ITG 6147)[30], as becomes
apparent when applying the programme RFLP on the 16S
rRNA sequence data we obtained. Similarly, strains that
we classified as M. fortuitum A and B [12], appear to corre-
spond to M. fortuitum subsp. fortuitum, resp. M. peregri-
num.
Materials and Methods
Strains
A collection of well characterized reference strains belong-
ing to different mycobacterial species was used to create
an ARDRA profile library. The strains used are listed in Ta-
ble 1. The 151 clinical strains used in this evaluation were
collected during the period between January 1998 and
December 2000 in the routine clinical laboratory of the
Ghent University Hospital.
Processing and culturing of the samples
Decontamination of the samples was done by mixing 1
ml of sample with 1 ml of decontamination buffer (3%
NaOH/N-acetyl L-cysteine (NALC)). After 15 min of incu-
bation at room temperature the mixture was neutralized
by adding 40 ml of 0.067 M phosphate buffer (pH 6.8),
followed by centrifugation at 11600 g during 15 min. The
supernatant was removed and part of the pellet was used
for auramine staining and microscopy. The remaining pel-
let was suspended in 1 ml of phosphate buffer and used
for inoculation of culture media. 100 µl was used for in-
oculation of a solid medium (Ogawa, Sanofi-Pasteur,
Marnes la Coquette, France) and 500 µl for the inocula-
tion of a liquid medium. During this study the automated
liquid culture system was changed from the Bactec system
(Becton Dickinson, Cockeysville, Md.) to the 3D BacT/
Alert system (Organon Teknika, Boxtel, The Netherlands).
DNA extraction
Starting from liquid culture, 500 µl of a positive culture
was transferred to a 1.5 ml screw cap Eppendorf tube. Af-
ter centrifugation at 13.000 rpm for 15 minutes, the su-
pernatant was removed and the resulting pellet was
resuspended in 50 µl TE buffer (100 mM Tris-HCl – 10
mM EDTA, pH 8.0). The mixture was heated for 30 min-
utes at 95°C, followed by a freezing step at -20°C for at
least 30 minutes. Starting from solid culture, a loopful of
a bacterial colony was suspended in 500 µl of TE buffer.
The mixture was heated at 95°C for 30 minutes, followed
by a freezing step at -20°C for at least 30 minutes. Prior to
PCR, DNA extracts were thawed at 4°C and centrifuged
shortly to pellet the debris.
ARDRA for mycobacteria consists of the amplification of
the 16S rRNA gene, followed by separate restriction diges-
tion with HhaI, MboI and RsaI The combination of the
three obtained fingerprints is designated an ARDRA pro-
file which can be compared with a library of ARDRA pro-
files, obtained from well-identified mycobacterial strains.
In some cases, more discriminatory identification is pos-
sible by additional restriction with BstUI.
Amplification of the 16S rRNA gene
The primers used to amplify the full length 16S rRNA gene
(approximately 1500 bp) were MBUZ1 (GAC GAA CGC
TGG CGG CGT GCT TAA C) and MBUZ2 (CGT CCC AAT
CGC CGA TC). These primers are designated to amplify
only the 16S rRNA gene for species of the order Actinomy-
cetales. The PCR mixture consisted of 25 µl Qiagen Mas-
termix (Qiagen, Hilden, Germany), 0.2 µM of each
primer, 5 µl of DNA extract, and was adjusted to 50 µl
with distilled water. Thermal cycling consisted of an ini-
tial denaturation of 5 min at 94°C, followed by three cy-
cles of 1 min at 94°C, 2 min at 55°C and 1 min at 72°C,
followed by 30 cycles of 20 sec at 94°C, 1 min at 55°C and
1 min 72°C, with a final extension of 7 min at 72°C, and
cooling at 10°C.
Amplification of 123 bp of the IS6110 region was carried
out as described [29] after DNA extraction from decon-
taminated sputum samples using the QiaAmp Tissue kit
(QiaGen, Hilden, Germany).
Restriction digestion
The restriction enzymes used were HhaI (isoschizomer of
CfoI)(Amersham Pharmacia Biotech Benelux, Roosend-
aal, the Netherlands), MboI (Fermentas, Vilnius, Lithua-
nia), RsaI (Amersham Pharmacia). When necessary for
further discrimination, digestion with BstUI (New Eng-
land Biolabs, Beverly, Ma.) was carried out. Each 16S
rDNA amplicon was divided in three separate tubes in al-
iquots of 10 µl, to which 10 U of the respective restriction
enzymes were added, with 2 µl of the corresponding en-BMC Microbiology 2002, 2 http://www.biomedcentral.com/1471-2180/2/4
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Figure 8
Neighbour-joining similarity tree for 16S rRNA gene sequences of most mycobacterial species. Legend: N. asteroides ATCC
49872 (Genbank Z82229) was used as the outgroup. Table 1 lists the GenBank accession numbers of the sequences used to
construct this tree. ARDRA patterns for HhaI, MboI, RsaI and BstUI are listed after the species name. a: GenBank AF028712.
Erroneously listed in GenBank as M. peregrinum (see also legend of Table 1). b: M. gastri clusters below 100% with M. kansasii,
although it is generally agreed that the 16S rRNA gene sequences for M. kansasii and M. gastri are identical. This can be
explained by the fact that the only available GenBank M. gastri sequence (X52919) contained several ambiguities. c. M. lentifla-
vum, initially not included in the manuscript is not presented in this tree. It clusters close to the branch including M. heidelber-
gense, M. simiae, M. triplex and M. genavense.
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zyme buffer (10×  concentrated, final concentration 2× )
and each restriction digestion mixture was adjusted to 20
µl with distilled water and incubated during 2 hours at
37°C in a heater.
Electrophoresis
The DNA restriction fragments were electrophoresed in a
2.5% agarose electrophoresis gel, containing 2% Meth-
aphor (FMC Bioproducts, Rockland, Me.) and 0.5% MP
agarose (Roche) in the presence of ethidium bromide (50
ng/ml). The gels were photographed and the fingerprints
were compared visually with the overview gels (Figures 1,
2 and 3).
16S rDNA sequencing and comparative analysis
A fragment of the 16S rRNA gene (corresponding to posi-
tions 10-1507 in the Escherichia coli numbering system)
was sequenced as described previously [31]. Sequencing
primers were MB UZ1 (GACGAACGCTGGCGGCGTGCT
TAAC,  E. coli position 27-50), MB UZ2 (CGTC-
CCAATCGCCGATC, 1493 – 1476), MBP1 (CCG-
GCCAACTACGTGCCAGC, 502 – 522), MBP2
(CTGGAATTCCTGGTGTAGCGG, 673 – 693), MBP3R
(GCATGTCAAACCCAGGTAAGG, 1006 – 986) and
MBP4R (CCACCTTCCTCCGAGTTGACC, 1185 – 1165)
The 16S rDNA sequences obtained in this study are indi-
cated in Table 1. All steps of the comparative sequence
analysis were performed by using the GeneBase software
package (Applied Maths, St. Martens Latem, Belgium), as
described [32]. First, pairwise alignment using UPGMA
was carried out with a gap penalty of 100 %, a unit gap
cost of 20 % and an ambiguity cost of 50 % of the mis-
match cost. Subsequently, global alignment – with N. as-
teroides ATCC 49872 (Genbank Z82229) used as the
outgroup – was carried out on the region corresponding
to positions 67 through 1444 of the 16S rRNA gene of E.
coli, with costs as above. Finally, a similarity matrix of the
aligned sequences was constructed by global alignment
homology calculation and a gap penalty of 20 %. The
neighbour-joining method was used to construct the den-
drogram based on this similarity matrix. Bootstrap values
were calculated.
Theoretical calculation of restriction patterns was done by
means of RFLP (Applied Maths), which makes it possible
to obtain restriction patterns using sequences in EMBL
format, for every restriction enzyme. The programme Gel-
Compar (Applied Maths) was then used to display the ob-
tained fingerprints.
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